HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low-dose rasburicase in hematologic malignancies.

AbstractOBJECTIVE:
To define the efficacy and safety of low-dose rasburicase in children from south India with hematologic malignancies.
METHODS:
This study is a retrospective analysis of data on 41 children with hematologic malignacies with laboratory evidence of tumor lysis syndrome (TLS) or clinical features indicating high risk for developing TLS. Patients were treated with rasburicase in doses of 0.1-0.15 mg/kg dose, repeated when necessary.
RESULTS:
Male : Female ratio was 32:9. Thirty-six children had laboratory evidence of TLS and 5 were at risk for TLS. Diagnoses were T-cell acute lymphoblastic leukemia (ALL), 19; Pre-B ALL, 17; B-non-Hodgkin lymphoma (NHL), 2; T-NHL, 2; and acute myeloid leukemia (AML), 1. Initial plasma uric acid (PUA): median, 8.5 mg/dl (range, 4.3 to 45.5). Six had creatinine levels of >2 mg/dl on admission; and 10 had peak PO4 levels of >10 mg/dl. Dose of rasburicase used: median, 0.12 mg/kg (range, 0.08-0.24). Median reduction of PUA at 6 h: 80 % (range 40 to 98 %). Twenty-seven needed only one dose; 12 needed 2 or 3 doses; and two needed 5 doses each. One child required dialysis. None of the children developed anaphylaxis or hemolysis and there were no deaths from TLS.
CONCLUSIONS:
Low-dose rasburicase (0.1-0.15 mg/kg) is safe and effective in reducing PUA in Indian children with lymphoid malignancies, and thus it may reduce the risk of renal failure from TLS.
AuthorsSomasundaram Jayabose, Vignesh Kumar, Rajeswari Dhanabalan, Priya Rajan, Krishnakumar Rathnam, T Kasi Viswanathan
JournalIndian journal of pediatrics (Indian J Pediatr) Vol. 82 Issue 5 Pg. 458-61 (May 2015) ISSN: 0973-7693 [Electronic] India
PMID25338496 (Publication Type: Journal Article)
Chemical References
  • Gout Suppressants
  • rasburicase
  • Uric Acid
  • Urate Oxidase
Topics
  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Gout Suppressants (administration & dosage, adverse effects)
  • Hematologic Neoplasms (drug therapy)
  • Humans
  • India
  • Infant
  • Male
  • Retrospective Studies
  • Tumor Lysis Syndrome (drug therapy)
  • Urate Oxidase (administration & dosage, adverse effects)
  • Uric Acid (blood)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: